CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane

被引：0

作者：

O'Shaughnessy, Joyce ^{[1
]}

Piccart, Martine ^{[2
]}

Schwartzberg, Lee ^{[3
]}

Cortes, Javier ^{[4
,5
,6
,7
]}

Harbeck, Nadia ^{[8
]}

Im, Seock-Ah ^{[9
]}

Rugo, Hope ^{[10
]}

Untch, Michael ^{[11
]}

Yardley, Denise ^{[12
,13
]}

Bondarenko, Igor ^{[14
]}

Dieras, Veronique ^{[15
]}

Pegram, Mark ^{[16
]}

Kroll, Stew ^{[17
]}

O'Connell, Joseph ^{[17
]}

Vacirca, Jeff ^{[17
]}

Wei, Thomas ^{[17
]}

Tang, Kevin ^{[17
]}

Seidman, Andrew ^{[18
]}

机构：

[1] Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA

[2] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[3] West Canc Ctr, Memphis, TN USA

[4] IOB Inst Oncol, Quironsalud Grp, Madrid, Spain

[5] Vall dHebron Inst Oncol, Madrid, Spain

[6] IOB Inst Oncol, Quironsalud Grp, Barcelona, Spain

[7] Vall dHebron Inst Oncol, Barcelona, Spain

[8] Univ Munchen LMU, Brustzentrum, Munich, Germany

[9] Seoul Natl Univ Hosp, Seoul, South Korea

[10] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA

[11] Helios Hosp Berlin Buch, Berlin, Germany

[12] Sarah Cannon Res Inst, Nashville, TN USA

[13] Tennessee Oncol, Nashville, TN USA

[14] Dnipropetrovsk Med Acad, Dnipro, Ukraine

[15] Ctr Eugene Marquis, Rennes, France

[16] Stanford Womens Canc Ctr, Palo Alto, CA USA

[17] Odonate Therapeut Inc, San Diego, CA USA

[18] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-OT1-08-09

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OT1-08-09

引用

页数：3

共 50 条

[1] CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor plus (HR plus ) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.
O'Shaughnessy, Joyce
Piccart, Martine
Schwartzberg, Lee S.
Cortes, Javier
Harbeck, Nadia
Im, Seock-Ah
Rugo, Hope S.
Untch, Michael
Yardley, Denise A.
Bondarenko, Igor
Chan, Stephen
Dieras, Veronique
Pegram, Mark D.
Kroll, Stew
O'Connell, Joseph P.
Vacirca, Jeff
Wei, Thomas
Tang, Kevin
Seidman, Andrew David
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[2] CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane
Schwartzberg, Lee
Asselah, Jamil
Bondarenko, Igor
Chae, YeeSoo
DaCosta, Noshir
Feng, Yin-Hsun
Izarzugaza, Yann
Lemieux, Julie
Liu, Mei-Ching
Marx, Gavin
O'Shaughnessy, Joyce
Oliveira, Mafalda
Rugo, Hope
Seidman, Andrew
Wright, Gail
O'Connell, Joseph
Wei, Thomas
Kim, Sung-Bae
CANCER RESEARCH, 2020, 80 (04)
[3] Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane
O'Shaughnessy, Joyce
Schwartzberg, Lee
Piccart, Martine
Rugo, Hope S.
Yardley, Denise A.
Cortes, Javier
Untch, Michael
Harbeck, Nadia
Wright, Gail S.
Bondarenko, Igor
Glaspy, John
Nowecki, Zbigniew
Kayali, Fadi
Chan, Arlene
Levy, Christelle
Liu, Mei-Ching
Kim, Sung-Bae
Lemieux, Julie
Manikhas, Alexey
Tolaney, Sara
Lim, Elaine
Gombos, Andrea
Stradella, Agostina
Pegram, Mark
Fasching, Peter
Mangel, Laszlo
Semiglazov, Vladimir
Dieras, Veronique
Gianni, Luca
Danso, Michael A.
Vacirca, Jeff
Kroll, Stew
O'Connell, Joseph
Tang, Kevin
Wei, Thomas
Seidman, Andrew
CANCER RESEARCH, 2021, 81 (04)
[4] Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor plus (HR plus ) locally advanced or metastatic breast cancer (MBC).
O'Shaughnessy, Joyce
Piccart-Gebhart, Martine J.
Schwartzberg, Lee Steven
Cortes, Javier
Harbeck, Nadia
Im, Seock-Ah
Rugo, Hope S.
Untch, Michael
Yardley, Denise A.
Bondarenko, Igor
Chan, Stephen
Dieras, Veronique
Gianni, Luca
Pegram, Mark D.
Kroll, Stew
O'Connell, Joseph P.
Vacirca, Jeffrey L.
Wei, Thomas
Tang, Kevin
Seidman, Andrew David
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[5] Results From CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor+ Metastatic Breast Cancer Who Have Previously Received a Taxane
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 9 - 10
[6] Results From CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor+ Metastatic Breast Cancer Who Have Previously Received a Taxane
O'Shaughnessy, Joyce
Schwartzberg, Lee
Piccart, Martine
Rugo, Hope S.
Yardley, Denise A.
Cortes, Javier
Untch, Michael
Harbeck, Nadia
Wright, Gail S.
Bondarenko, Igor
Glaspy, John
Nowecki, Zbigniew
Kayali, Fadi
Chan, Arlene
Levy, Christelle
Liu, Mei-Ching
Kim, Sung-Bae
Lemieux, Julie
Manikhas, Alexey
Tolaney, Sara
Lim, Elaine
Gombos, Andrea
Stradella, Agostina
Pegram, Mark
Fasching, Peter
Mangel, Laszlo
Semiglazov, Vladimir
Dieras, Veronique
Gianni, Luca
Danso, Michael A.
Vacirca, Jeff
Kroll, Stew
O'Connell, Joseph
Tang, Kevin
Wei, Thomas
Seidman, Andrew
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 12 - 13
[7] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane.
Schwartzberg, Lee S.
Bondarenko, Igor
Tolaney, Sara M.
Seidman, Andrew David
O'Shaughnessy, Joyce
Shparyk, Yaroslav V.
Chung, Chi-Feng
Lu, Yen-Shen
Chic, Nuria
Panasci, Lawrence C.
Chae, Yee Soo
Recalde, Sabela
Hotko, Yevhen
Gomez, Patricia
Shaw Wright, Gail Lynn
Anthony Dacosta, Noshir
Vatandoust, Sina
O'Connell, Joseph P.
Wei, Thomas
Rugo, Hope S.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[8] Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor plus (HR plus ) locally advanced or metastatic breast cancer (MBC) in a phase 2 study
Seidman, Andrew David
Schwartzberg, Lee Steven
Gudena, Vinay K.
Rubin, Peter
Kroll, Stew
O'Connell, Joseph P.
Tang, Kevin
O'Shaughnessy, Joyce
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
Rugo, H.
Tolaney, S.
Dickler, M.
Kabos, P.
Ho, C-L
Wildiers, H.
Jerusalem, G.
Ales-Martinez, J. E.
Hossain, A.
Johnston, E.
Gianni, L.
CANCER RESEARCH, 2017, 77
[10] CONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2-metastatic breast cancer (MBC)
Tolaney, S. M.
Blum, J. L.
Bondarenko, I.
Chan, A.
DaCosta, N.
Feng, Y. -H.
Izarzugaza, Y.
Kim, S. -B.
Liu, M. -C.
Oliveira, M.
Ow, S. G. W.
Pavic, M.
Perez Lopez, M. E.
Rugo, H. S.
Schwartzberg, L.
Stradella, A.
Kroll, S.
O'Connell, J.
Wei, T.
Mittendorf, E. A.
ANNALS OF ONCOLOGY, 2019, 30 : 138 - +

← 1 2 3 4 5 →